On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive catalysts accumulated over recent weeks.

On the news front, RBC Capital Markets initiated coverage on June 12 with an Outperform rating and a $185 price target, noting that only approximately 25% of metastatic cancer patients in the US currently receive genomic profiling, positioning Guardant as the market leader best poised to benefit from expanding adoption. Additionally, on June 11, the FDA approved Guardant360 CDx as a companion diagnostic for non-small cell lung cancer therapy. These developments build on Q1 results that significantly beat expectations, with adjusted EPS of -$0.45 versus the -$0.76 consensus estimate and revenue of $301.7 million versus the $279.2 million estimate. The company also raised its full-year revenue guidance to $1.30B-$1.32B, above the prior FactSet estimate of $1.27B.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)